INTERIM REPORT 3RD QUARTER 2013

Q3

Letter from the Management Board

Dear shareholders,
Ladies and Gentlemen,

As already reported, during the first half of the year Alphaform got into the loss-zone principally due to declining prices. Even in August it seemed that the upturn in business with improved prices during the second half of the year could mostly compensate the disappointing performance of the first half. In fact, as a consequence of a stable economic situation again, we have noted since July a permanent order increase in the 3D printing and additive manufacturing sector. The client rewards our positioning as quality-supplier of additive manufactured work pieces: Where we were not bound by long-term fixed agreements, we were able to raise the prices again to the level of the previous year - the sector is clearly profitable again. Furthermore, we were able to extend our business model through the online marketing of high-quality design and art works: The joint venture project that has been prepared since about one year together with the experienced E-commerce partner Tiburon named Artshapes starts now. In addition to the potential business impulses, we expect efficiency improvements also in our core business through an automated project management from object testing through buildability up to the production planning.

Nevertheless, with a third quarter at € 7 million – one with the highest revenue until present – we did not generate profit. On the one hand due to the development expenses for Artshapes, on the other hand because of the slow running business in the medical division. Although in general the business development of the medical division has improved compared to the first half of the year, many of our casting customers have ordered hesitantly during the last quarters. Our subsidiary MediMet has been affected because of this over the entire year until date. As a consequence, there was a constant decrease in the production volume that we could not compensate fast enough with fixed costs reduction. Even if the incoming orders have been increasing significantly since September, we cannot estimate whether this means a positive turning point for the complete fourth quarter. Absolutely positive was the development of the CNC-processing in Eschenlohe during the last months: Backlog, utilization and profitability have increased significantly again.

The tasks to be performed during the takeover and restructuration of MediMet have proven to be extremely complex: First, the incoming orders overloaded the capacities and then, the precipitately accelerated production occasioned too high costs, so that deficits in the forward-looking estimation of the customer demands appeared. Also the management adjustments regarding the integration into the Alphaform Group did not function optimally. However, we are still convinced of the strategic logic of this acquisition and we are confident that with the new personnel reinforcements we are able to bring MediMet in the profit zone again and keep it there. Though, this process will still be drawn into the next year.

The slightly negative result in the third quarter will probably be complemented with a balanced result in the fourth quarter. For the entire year 2013 this development means that we cannot compensate the loss in the first half of the year as expected. We now expect revenue of about €26 million and an operating loss amounting to the status at the end of the third quarter. Moreover, due to the described situation at MediMet we must anticipate a Goodwill-impairment for the subsidiary whose amount still has to be defined.

Yours

Dr Thomas Vetter

Alphaform in the third quarter 2013: Noticeable recovering in 3D-printing – Restructuring of Medical Division delayed

The key figures for the third quarter of the fiscal year 2013 are as follows:

- At €6.9 million, revenue in the third quarter of 2013 was above by 2.7% compared to the same period of the previous year. For the period between 1st of January to 30rd of September revenue reduced by 6.2%, from €20.8 million in year 2012 to €19.5 million in year 2013.

- As at 30rd of September 2013, booked business amounted to €2.6 million. In the previous year as at 30rd September 2012 they amounted to €3.3 million.

- EBITDA declined to €0.250 million in the third quarter of 2013 compared to €0.517 million in the same period of the previous year. During the first nine months EBITDA reduced from €1.678 million in 2012 to €-0,038 million in year 2013.

- Net result after interest and taxes reduced by €0.3 million in the third quarter of 2013 compared to the same period of the previous year, from €0.1 million to €-0.2 million. For the period between 1st of January to 30rd of September net result after interest and taxes reduced by €1.8 million, from €0.5 million in year 2012 to €-1.2 million in year 2013.

- Earnings per share reduced in the third quarter, from €0.03 in year 2012 to €-0.03 in 2013, as well as in the first nine months from €0.10 in year 2012 to €-0.23 in 2013.

- Cash flow from operating activities in the first nine months of the fiscal year 2013 was with €0.519 million by €0.046 million higher compared to the same period of the previous year at €0.473 million.

- As at 30rd September 2013, the group employed 235 full-time equivalents (compared to the previous year as at 30rd September: 242).

Key figures of the Alphaform Group

T€, exept employees and earnings per share	Quarter 3			1 January - 30 September		
	2013	2012	Change in %	2013	2012	Change in %
Revenue	6.935	6.755	2,7	19.543	20.838	-6,2
EBITDA	250	517	-51,6	-38	1.678	-102,3
Operating result	-73	196	-137,2	-965	704	-237,1
Result after tax	**-177**	**137**	**-229,2**	**-1.244**	**524**	**-337,4**
Earning per share	-0,03	0,03	-200,0	-0,23	0,10	-330,0
Equity as of September 30 (2012 as of Dec, 31)				11.544	12.782	-9,7
Total assets as of September 30 (2012 as of Dec, 31)				20.277	21.385	-5,2
Equity ratio (percent)				56,9	59,8	-4,8
Cash and cash equivalents and securities as of September 30 (2012 as of Dec, 31)				1.126	1.633	-31,0
Group employees as of September, 30				235	242	-2,9

Interim Group management report

Company development / sector overview

During the third quarter, revenues in the 3D printing and additive manufacturing sector rose almost to the same level of the second quarter of 2012. Thus, the past quarter was the second strongest in the last years for this sector. 3D printing and additive manufacturing has been specially supported by a revival in the automotive industry and recovery in prices. Earnings were unsatisfactory because running frame work agreements of the weak quarters 4/2012 and 1/2013 prevented a rapid price recovery.

Also apart from the automotive industry we experience a continuously growing demand for additive manufacturing technologies in all customer industries, especially in laser sintering. At the same time, public interest for 3D printing rises quickly. Thus, the foundation of our joint venture company “Artshapes” with the seed investor Tiburon motivated many media reports, as well as inquires of interested persons to Alphaform even before the operational activities started. Artshapes sells high quality, additive manufactured design and art works through an own Internet platform. Overall, the 3D printing and additive manufacturing sector has already overcome the decline of demand and related price slump (see segment reporting).

In the medical division, demand has stabilized at a very low level during the second quarter. The third quarter showed a slight but constant upward trend month after month. Especially, Alphaform-Claho benefited from this, where overall development including profitability has been successful already during the complete running fiscal year. Nevertheless, at MediMet total volumes remained noticeably under the figures needed for a profitable business also in the third quarter. Then, in October, we experienced a clear push in incoming orders at MediMet. However, the trend is still unclear. Anyhow, only the incoming orders in October 2013 for the medical division represented 60% of the incoming orders during the complete third quarter. MediMet recorded as many orders in one month, as since December 2011.

At MediMet, personnel reinforcement in the Production and Sales departments were effective by the end of the quarter. This should contribute to lead to success our efforts for a sustainable raise of the company´s profitability. As before, the market trend in orthopaedic implants remains intact, so we are confident that we can bring MediMet during the next business year back to profit.

Alphaform subsidiaries in Scandinavia and the UK continued developing positive. As already mentioned in the half-year report, they made a positive growth of total 7.8% in all activities.

EBITDA decreased from €0.5 million in the third quarter of 2012 to €0.3 million in the reported period. During the first nine months EBITDA reduced from €1.7 million in year 2012 to €0.0 million in 2013. Nevertheless, compared to the first half of the year, there was a comeback into the operational profitability zone during the third quarter, which is mainly due to better prices again in 3D printing and additive manufacturing. The gross profit margin decreased in the third quarter to 64.1% compared to 64.6% in the previous year. Also here - thanks to the positive price development - a slight improvement of 0.3% was achieved compared to the first half of the year 2013.

Net assets financial position and operational results

Revenue development and order situation

Compared to the same period of the previous year, group revenue declined by 6.2% to €19.543 million, starting at €20.838 in the first nine months of 2012.

The order backlog of the Group amounted to €2.6 million at the end of the third quarter of 2013. The order backlog decreased by 21.2% compared to the same deadline in the previous year (order backlog at 30rd September 2012: €3.3 million).

Material costs and gross margin

In the third quarter of 2013, the generated gross margin with 64.1% was by 0.5% lower compared to the same period in 2012 with 64.6%.

The material costs increased by €0.248 million in the third quarter of 2013 compared to 2012, from €2.242 million to €2.490 million.

Operational costs

The net result of the Alphaform Group reduced by €0.314 million in the third quarter of 2013 compared to the same period of the previous year, from €0.137 million in the third quarter of 2012 to €-0.177 million in the third quarter of 2013.

Staff costs

Staff costs reduced by €0.066 million in the third quarter of 2013 compared to the same period of the last year, which represents a reduction of 2.5%

Depreciation and amortisation expenses

The amount of depreciation and amortisation expenses increased slightly in the third quarter of 2013 compared to the same period of the previous year. Depreciation and amortisation expenses amounted to €0.323 million in the third quarter of 2013 and therefore, they were higher by 0.6% than in the third quarter of 2012 (€0.321 million).

Other operating expenses

At €1.608 million in the third quarter of 2013, other operating expenses are by €0.419 million higher than in the same period of the previous year (at €1.189 million).

Financing and cash flow

The consolidated cash flow of the group shows the origins and use of the cash flow in the first nine months of the fiscal years 2013 and 2012. For this case, cash flow is split into those from the current operating activity and those from investing and financing activities.

In the third quarter of 2013, cash flow from operating activities amounted to €0.519 million and was by €0.046 million over the cash flow of the same period of the previous year at

€0.473 million. The main reason for the higher cash flow in relation to the previous year is the improvement in working capital management despite the bad result.

In the third quarter of 2013, the cash drain resulting from investment activities amounted to €0.737 million, whereat most of it results from the acquisition of fixed assets.

Cash flow from financing activities generated a cash drain of €0.234 million in the third quarter of 2013, which amounted to €0.234 million and is caused by a stronger redemption. Compared to the same period of the previous year, there was a cash drain of €0.608 million due to the repayment of bank loans.

Cash and cash equivalents decreased by €0.195 million compared to the same period of the previous year. Until the deadline on 30rd September 2013, available cash and cash equivalents amounted to €1.126 million compared to €1.321 million until the deadline on 30rd September 2012.

Balance sheet

As at 30rd September 2013, total assets amounted to €20.277 million, which represents a reduction by €1.108 million compared to the balance value until the deadline on 31st December 2012 (€21.385 million). The equity ratio reduced from 59.8% as at 31st December 2012 to 56.9% as at 30rd September 2013.

The biggest changes compared to the end of the year 2012 are related to the items cash and cash equivalents. Cash reduced by €0.507 million, from €1.733 million as at 31st December 2012 to €1.226 million as at 30rd September 2013. Cash equivalents reduced by €0.867 million from €3.526 million as at 31st December 2012 to €2.659 as at 30rd September 2013. The main reason: Working capital improvement.

Employees

As at 30rd September 2013, our company employed 235 (FTEs). This represents a reduction of 2.9% compared to the same deadline of the previous year. At present, the Alphaform Group employs 8 trainees.

As at 30rd September 2013 and 30rd September 2012, the employees' structure was represented as follows:

	Quarter 3		
	2013	2012	Veränderung in %
Alphaform AG	92	90	2,2
Alphaform-Claho GmbH	43	41	4,9
Alphaform RPI Oy, Finnland	16	16	0,0
Alphaform Ltd., Großbritannien	2	2	0,0
Alphaform-Projekt GmbH	0	0	0,0
MediMet GmbH	82	93	-11,8
employees group total	**235**	**242**	-2,9

Reports of risk and forecast

A significant proportion of the Alphaform Group revenue is generated by project orders of the automotive industry as well as by serial orders of medical orthopaedics. These industries are particularly characterised by a persistent pressure on suppliers, an aggressive price competition, strict development budgets and shorter project terms.
In terms of risk management and costs reduction, both sectors set on second and third alternative suppliers, in order to shift quickly their main sourcing activities to other providers. The development scenario in the automotive industry is changing in favour of an increased development service for the automotive suppliers and the engineering service providers. As it is not always possible for us to predict these processes, they represent a significant risk for the full utilisation of our capacities and hence for our results. Furthermore, consolidation trends are observed among large market players (OEMs) in the medical technology area, which also entail the risk of increasing price pressure in the supplier sector.

Outlook

The economic situation forecasts for Germany and Europe have slightly improved. For the year 2014, leading economic institutions expect a good growth of 1.8% for Germany and the end of the recession in Europe. This should also have a positive impact on the Alphaform business, even though not yet in the present business year.

For the fourth quarter we expect a steady upward trend, which, however, will only have a marginal effect in the balance figures for the moment. This is due to different reasons: In case that the present positive orders development at MediMet continues, this will just influence the profit in the following fiscal year. The new Internet sales platform Artshapes will cause start-up costs at the beginning. December is a rather weak month for the 3D printing and additive manufacturing sector, which depends strongly on the activity of the development departments. We still expect upward pulses from our new DMLS application centre for serial production in Eschenlohe (DMLS = Direct Metal Laser Sintering), but here the balance sheet effects would only be visible in the course of the next year.

The slightly negative result in the third quarter will probably be complemented with a balanced result in the fourth quarter. For the entire year 2013 this development means that we cannot compensate the loss in the first half of the year as expected. We now anticipate revenues of about €26 million and an operating loss amounting to the status at the end of the third quarter. Moreover, due to the described situation at MediMet we must expect a Goodwill-impairment for the subsidiary whose amount still has to be defined.

Feldkirchen, 8th November 2013

Dr Thomas Vetter
CEO, Alphaform AG

Group – Consolidated statement of comprehensive income

In T€, with the exception of earnings per share and number of shares	Quarter 3		1 January - 30 September	
	2013	2012	2013	2012
Revenues	6.935	6.755	19.543	20.838
Changes in inventories	-94	10	-352	-19
Other operating income	97	-161	212	383
Cost of materials	-2.490	-2.242	-6.977	-6.740
Gross profit	**4.448**	**4.362**	**12.426**	**14.462**
Personnel expenses	-2.590	-2.656	-7.927	-8.185
Depreciation and amortisation costs and other write-offs	-323	-321	-927	-974
Other operating expenses	-1.608	-1.189	-4.537	-4.599
Operating result	**-73**	**196**	**-965**	**704**
Other interest and similar income	1	2	2	9
Interest and similar expenses	-103	-59	-278	-183
Result before tax	**-175**	**139**	**-1.241**	**530**
Other taxes	-2	-2	-3	-6
Result after tax	**-177**	**137**	**-1.244**	**524**
Allocations of profit or loss				
profit or loss attributable to minority interest	**-1**	**2**	**6**	**3**
Gross profit / loss	**-178**	**139**	**-1.238**	**527**
Profit/loss per share				
Profit/loss per share (basic)	-0,03	0,03	-0,23	0,10
Profit/loss per share (diluted)	-0,03	0,03	-0,23	0,10
Weighted average number of shares outstanding (basic)	5.318.209	5.318.209	5.318.209	5.318.209
Weighted average number of shares outstanding (diluted)	5.318.209	5.318.209	5.318.209	5.318.209

Group – Statement of financial position

T€	30 September 2013	31 December 2012
Assets		
Cash and cash Equivalents	1.226	1.733
free cash	1.126	1.633
resticted cash	100	100
Trade accounts receivable	2.659	3.526
Inventories	4.593	4.593
Other current assets	1.459	958
Total current assets	9.937	10.810
Property and equipment, net	4.056	4.193
Intangible assets, net	5.381	5.430
Cash and cash Equivalents	887	932
resticted cash	887	932
Deferred Tax asset	12	12
Other non-current assets	4	8
Total noncurrent assets	10.340	10.575
Total Assets	**20.277**	**21.385**

T€	30 September 2013	31 December 2012
Liabilities and shareholders' equity		
Common stock, € 1 par value	5.318	5.318
Additional paid-in capital	11.325	11.325
Accumulated other comprehensive loss	6	0
Accumulated profit/loss	-5.105	-3.861
Total shareholders' equity	11.544	12.782
Noncurrent liabilities		
Liabilities due to banks	463	804
Other liabilities	1.317	1.207
Finance lease obligations	311	454
Current liabilities		
Current finance lease obligations	236	235
Liabilities due to banks	1.147	898
Trade accounts payable	3.061	2.428
Other provisions/liabilities	2.198	2.577
Total liabilities	8.733	8.603
Total liabilities and shareholders' equity	**20.277**	**21.385**

2012 and 2013: 5,318,209 shares per € 1 par value

2012 and 2013 authorised capital stock € 2,659,104, 2012 and 2013 conditional capital €531,820

Group – Consolidated terms of cash flows

	1 January - 30 September	
	2013	**2012**
T€		
Result after taxes	-1.244	524
Adjustments reconcile net profit/loss to net cash from/used in operating activities		
Depreciation of property, plant and equipment	840	974
Depreciation of intangible assets	87	0
Sale of property, plant and equipment at residual value	0	153
Currency translation differences	6	-15
Changes in operating assets and liabilities:		
Trade receivables	867	-557
Inventories	0	-329
Other current assets	-501	363
Restricted cash	100	-154
Liabilities	633	-130
Other provisions and liabilities	-269	-356
Net cash from operating activities	**519**	**473**
Acquisition of property, plant and equipment, excl. finance leases	-703	-633
Proceeds from the sale of property, plant and equipment, excl. finance leases	0	0
Expenses for other loans	-34	12
Acquisition of subsidiaries	0	-75
Net cash used in investing activities	**-737**	**-696**
New Bank Loans	249	414
Principal payments on bank loans	-341	-851
Principals payments under finance leases	-142	-171
Net cash used in financing activities	**-234**	**-608**
Net reduction in cash and cash equivalents	-452	-831
Restricted cash	-55	600
Cash, cash equivalents and short term investments at beginning of period	1.633	1.552
Cash and cash equivalents includung short-term investments at the end of the period	**1.126**	**1.321**
Additional cash flow statement disclosures		
Cash paid for interest	278	183
Revenue for interest	2	9
Non-cash transactions:		
Property, plant and equipment acquired under finance leases	0	477

Group – Consolidated statement of changes in equity

All figures in € thousand exept number of shares	Common Stock: Number of shares	Common Stock: Amount	Additional paid-in-capital	Accumulated other comprehensive income	Accumulated profit / deficit	Total shareholders´ equity
IAS/IFRS shareholders´equity as of December 31, 2011	**5.318.209**	**5.318**	**11.325**	**9**	**(4.398)**	**12.254**
Result					524	524
Foreign currency translation				(12)		(12)
IAS/IFRS shareholders´equity as of September 30, 2012	**5.318.209**	**5.318**	**11.325**	**(3)**	**(3.874)**	**12.766**
IAS/IFRS shareholders´equity as of December 31, 2012	**5.318.209**	**5.318**	**11.325**	**0**	**(3.861)**	**12.782**
Result					(1.244)	(1.244)
Foreign currency translation				6		6
IAS/IFRS shareholders´equity as of September 30, 2013	**5.318.209**	**5.318**	**11.325**	**6**	**(5.105)**	**11.544**

Notes to the consolidated financial statement (shortened)

Basis of consolidation

The consolidated financial statements include Alphaform AG and all its associated companies in line with the method of full consolidation. In the 3rd quarter of 2013 there was no change in the Group compared to the status as at 31st December 2012.

As at 30rd September, the company held 100% of the shares in the following subsidiaries directly:

- Alphaform-Projekt GmbH, Feldkirchen 100%
- Alphaform Ltd., Newbury, UK 100%
- Alphaform-Claho GmbH, Eschenlohe 100%
- Alphaform RPI Oy, Rusko, Finland 100%
- MediMet Precision Casting and Implants Technology GmbH 100%

Basic accounting policies

Principles of reporting

The present report as at 30rd September 2013 was prepared in shortened form compared to the consolidated annual financial statements in accordance with the regulations of IAS 34 "Interim Financial Reporting".

The consolidated financial statements as at 31st December 2012 were prepared in accordance with the International Financial Reporting Standards (IFRS) of the International Accounting Standards Board (IASB) considering the interpretations of the International Financial Reporting Interpretations Committee (IFRIC).

The accounting and consolidation policies applied in this report as at 30rd September 2013 are the same as those used in the consolidated financial statements as at 31st December 2012

The accounting policies were applied consistently to all financial years presented in the financial statements. Expenses and incomes, which are incurred or generated not until the end of the financial year, are recognised by a period for purposes of interim financial reporting.

Further, we also apply the recommendations of Deutsche Börse on quarterly reporting by companies listed in the Prime Standard.

The interim consolidated financial statements were neither audited in line with section 317 of the German Commercial Code (HGB) nor reviewed by an auditor.

The same principles of consolidation were applied in preparing the interim financial statements and calculating comparative figures as for the 2012 consolidated financial statements.

Segment reporting

A business segment is a distinguishable component of a group that is engaged in providing products or services and that is exposed to risks and returns that are different from those of other business segments.

Segment information is provided on the Group's business and geographical segments. The basis for the primary segment-reporting format is the Group's management structure and its financial reporting system. Segments results contain components that are directly attributable to the individual segment or that can be reasonably allocated to the segments.

Business segments

The Group consists primarily of the following two business segments:

Additive Manufacturing / 3D printing

The business segment Additive Manufacturing / 3D printing comprises Alphaform AG, Feldkirchen, (including Group Administration), Alphaform RPI Oy, Finland, Alphaform Ltd., UK and Alphaform Projekt GmbH, Feldkirchen.

Medical Division

The business segment Medical Division comprises Alphaform-Claho GmbH, Eschenlohe, and MediMet GmbH, Stade.

Period from 1st January to 30rd September 2013:

T€	AM / 3D-Printing 2013	Medical Devision 2013	Not allocated 2013	Group 2013
External revenues	12.794	6.749	0	19.543
Revenues with other segments	0	964	-964	0
Revenues	**12.794**	**7.713**	**-964**	**19.543**
Segment earnings	**-477**	**-454**	**-34**	**-965**
Interest income	24	1	-23	2
Interest expenses	-213	-88	23	-278
Other expenses, net	0	0	0	0
Profit/loss before taxes	**-666**	**-541**	**-34**	**-1.241**
Income taxes	0	-3	0	-3
Net result for the period	**-666**	**-544**	**-34**	**-1.244**

Period from 1st January to 30rd September 2012:

T€	AM / 3D-Printing 2012	Medical Devision 2012	Not allocated 2012	Group 2012
External revenues	12.764	8.074	0	20.838
Revenues with other segments	8	1.015	-1.023	0
Revenues	**12.772**	**9.089**	**-1.023**	**20.838**
Segment earnings	**399**	**305**	**0**	**704**
Interest income	46	1	-38	9
Interest expenses	-124	-97	38	-183
Other expenses, net	0	0	0	0
Profit/loss before taxes	**321**	**209**	**0**	**530**
Income taxes	0	-6	0	-6
Net result for the period	**321**	**203**	**0**	**524**

Geographical segments

The geographical segments are divided into Central Europe and Northern Europe. Segment revenue information is related to the domicile of the respective customer.

The following table shows the geographical distribution of revenue:

Consolidated revenue from 1st January to 30rd September

	Central Europe		North Europe		not allocated		Total	
T€	2013	2012	2013	2012	2013	2012	2013	2012
Germany	10.369	10.665	0	0	0	0	10.369	10.665
Finland	40	0	1.499	1.559	0	0	1.539	1.559
UK	170	121	2.140	1.816	0	0	2.310	1.937
Rest of Europe	1.601	2.046	0	0	0	0	1.601	2.046
Rest of World	3.724	4.631	0	0	0	0	3.724	4.631
Total	**15.904**	**17.463**	**3.639**	**3.375**	**0**	**0**	**19.543**	**20.838**

Stock option plans

No stock options were issued to the Management Board or to the Supervisory Board in 2013 and 2012.

Related parties

There were no personnel changes within the Management Board or in the Supervisory Board in the third quarter of 2013.

The following table shows the shareholdings of the Management Board and the Supervisory Board as at 30rd September 2013:

	Position	Stock options as of 09/30/13	Shares as of 09/30/13	Percent of share capital[1]
Dr Thomas Vetter	Chief Executive Officer		125.321 [2]	2.36
Matti Paasila	Chairman of the Supervisory Board		60.000	1.13
Dr Hans J. Langer	Member of the Supervisory Board		976.659 [3]	18.36
Falk F. Strascheg	Member of the Supervisory Board		852.317 [4]	16.03
Total		**0.00**	**2.014.297**	**37.88**

1) 5.318.209 shares
2) Of which 53.180 shares held by Juana Parra
3) Of which 976.659 shares held by LHUM Vermögensverwaltungs GmbH
4) Of which 433.583 shares held in Renate Strascheg Holding GmbH;
Of which 418.734 shares in Falk Strascheg Holding GmbH

As at 30th September 2013 no stock options had been issued to members of the Management Board or the Supervisory Board. Alphaform AG has not granted any loans to members of the Management Board nor the Supervisory Board, but it has assumed a bank guarantee at Bankhaus Donner & Reuschel, Munich, for a loan to Dr Thomas Vetter amounting to €400 thousand.

Effective from the 1st February 2010, there is a consulting agreement between Alphaform AG and Mr Paasila independently of his position as the Chairman of the Supervisory Board of Alphaform AG. Mr Paasila supports the company in the implementation of its strategic reorientation with his particular expertise and his access to an international network on approximately 10-15 compensated consulting days per year, for a daily fee of €1.5 thousand. In particular, Mr Paasila plays an active role generating leads, analysing and assessing business (due diligence) and transaction pricing negotiations. Mr Paasila also advises the company on the operational incorporation of acquired companies into the Alphaform Group.

Other than this, there are currently no further consulting contracts with current or former members of the Supervisory Board.

As a member of the Supervisory Board of Alphaform AG, Dr Hans Langer is also the Chairman of the Management Board of EOS Holding AG in Krailling. EOS GmbH, a wholly owned subsidiary of EOS Holding AG, is one of the largest supplier of raw materials with a purchasing volume amounting to €0.7 million in the first nine months of 2013 (previous year: €0.6 million).

Events after the first nine months

The dispute with the former Board member Dr Guth has been terminated by mutual agreement. The resulting costs for the company have been considered in the financial figures published so far.

Financial calendar 2013:

German equity forum – Chances for individual meetings for investors and the CEO:
11th and 12th November 2013

Investors' day 2014: 29th January 2014

Publication of the Annual Report 2013: 28th March 2014

Investor Relations

E-Mail: ir@alphaform.de
Telephone (089) 90 500 2-35
Telefax (089) 90 500 2-1035

Alphaform AG
Kapellenstrasse 10
85622 Feldkirchen

This report is can be downloaded in English and German languages in Internet.